Enodia Therapeutics, a biotechnology company developing novel small-molecule therapies for targeted protein degradation at the point of synthesis, has entered into a research collaboration and license agreement with Pfizer to discover and develop Sec61 inhibitors. The collaboration aims to accelerate the discovery and advancement of novel small-molecule… Read More
Eli Lilly and Gate Bioscience have expanded their collaboration to discover, develop, and commercialise molecular gate therapeutics. The expanded collaboration adds one target, with the opportunity to add a second target, to the companies’ existing work. The programmes leverage Gate’s Molecular Gate drug discovery engine to identify medicines capable of… Read More
TRIMTECH Therapeutics has raised an additional $14 million in seed funding, bringing total investment for the company’s targeted protein degradation portfolio to $47 million. TRIMTECH has demonstrated its TRIMTAC and TRIMGLUE degraders can selectively degrade toxic protein aggregates and oligomers while leaving the functional monomeric forms of these proteins intact to… Read More
Alex Bentley, an 1851 Industrial Fellow working with GSK and the University of Strathclyde, discusses how his research into protein degraders will benefit drug discovery efforts across the pharmaceutical industry. First proposed in the early 2000s, targeted protein degradation (TPD) has emerged as a therapeutic modality with the potential to transform the… Read More
The kinetic profile of degrader compounds is critical to optimised design, showing how live-cell kinetic analysis transforms discovery. A new Whitepaper from Promega entitled ‘Beyond Endpoints: Capturing and Translating The Dynamics of Targeted Protein Degradation‘ reveals how tracking protein dynamics in live cells delivers richer, more actionable data to… Read More
The kinetic profile of degrader compounds is critical to optimised design, showing how live-cell kinetic analysis transforms discovery. This Whitepaper reveals how tracking protein dynamics in live cells delivers richer, more actionable data to improve compound optimisation across programmes. The Whitepaper will discuss: Why kinetic data deliver deeper context than… Read More
A new study in Structure, a Cell Press journal demonstrates that DCAF2 can be harnessed as a novel E3 ligase for targeted protein degradation (TPD). The authors say DCAF2 presents an exciting opportunity to deliver tumour-targeted protein degraders given its frequent overexpression in various types… Read More
Register now to secure your place at a new free-to-attend webinar on 23 September entitled ‘PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery’, hosted by DDW and supported by Revvity. Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted… Read More
Register now to secure your place at a new free-to-attend webinar on 23 September entitled ‘PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery’, hosted by DDW and supported by Revvity. Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted… Read More
Register now to secure your place at a new free-to-attend webinar on 23 September entitled ‘PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery’, hosted by DDW and supported by Revvity. Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted… Read More
Register now to secure your place at a new free-to-attend webinar on 23 September entitled ‘PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery’, hosted by DDW and supported by Revvity. Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted… Read More
Register now to secure your place at a new free-to-attend webinar on 23 September entitled ‘PROTAC-Mediated CDK2 degradation in oncology: Immunoassay tools for therapeutic discovery’, hosted by DDW and supported by Revvity. Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted… Read More
In this webinar, hosted by DDW and supported by Revvity, Audrey Johnson, a scientist at Beantown Biotech, explores the innovative application of targeted protein degradation (TPD) in oncology research, with a specific focus on CDK2 degradation for potential cancer treatments. Johnson is joined during the Q&A by Rachel Mendes, Senior… Read More
A research team at the University of Dundee have been recognised for their work with industry partner, Boehringer Ingelheim, with the Biochemical Society’s 2026 Industry and Academic Collaboration Award. The award ‘recognises and promotes an outstanding individual or team who has made an inspirational contribution to the… Read More
In a new study, published in Nature, Professor Yifat Merbl’s lab at the Weizmann Institute of Science reports uncovering a surprising immune mechanism involving the proteasome. The proteasome is a cellular waste disposal system best known for its central role in… Read More
TRIMTECH Therapeutics, a biotech company harnessing targeted protein degradation (TPD) for the treatment of neurodegenerative diseases, has closed a $31 million seed funding round. The investment will support further development of the company’s pipeline of central nervous system (CNS) penetrant therapeutics based on its aggregate-selective degrader molecules known as TRIMTACs. … Read More
